{"corpus_id":235887814,"paper_sha":"28b48203ead5503ad15f5cc4e8488d47b25a7398","doi":"10.1155/2021/5531873","arxiv_id":null,"pmid":34306612,"pmcid":"8285191","mag_id":null,"dblp_id":null,"acl_id":null,"title":"Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients","year":2021,"publication_date":"2021-07-07","venue":"International Journal of Inflammation","journal":{"name":"International Journal of Inflammation","pages":null,"volume":"2021"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":47,"citation_count":12,"influential_citation_count":1,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://downloads.hindawi.com/journals/iji/2021/5531873.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/28b48203ead5503ad15f5cc4e8488d47b25a7398","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Background The outbreak of Coronavirus Disease 2019 (COVID-19) has been increasing rapidly. This disease causes an increase in proinflammatory cytokine production that leads to cytokine storm or cytokine release syndrome (CRS). Autologous activated platelet-rich plasma (aaPRP) contains various types of growth factors and anti-inflammatory cytokines that may have the potential to suppress CRS. This study of phase I/II trial was aimed to evaluate the safety and efficacy of aaPRP to treat severe COVID-19 patients. Methods A total of 10 severe COVID-19 patients from Koja Regional Public Hospital (Koja RPH) were admitted to the intensive care unit (ICU). All patients received aaPRP administration three times. Primary outcomes involving the duration of hospitalization, oxygen needs, time of recovery, and mortality were observed. Secondary outcomes involving C-reactive protein (CRP), neutrophil, lymphocyte, and lymphocyte-to-CRP (LCR) and neutrophil-lymphocyte ratio (NLR) were analyzed. Results All patients were transferred to the ICU with a median duration of 9 days. All patients received oxygen at enrollment and nine of ten patients recovered from the ICU and transferred to the ward room. There was one patient who passed away in the ICU due to heart failure. The results of secondary outcomes showed that CRP value and lymphocytes counts were significantly decreased while neutrophils, LCR, and NLR were slightly increased after aaPRP administration. Conclusions Our results of the phase I/II trial demonstrated that the use of aaPRP in severe COVID-19 patients was safe and not associated with serious adverse events, which showed that aaPRP was a promising adjunctive therapy for severe COVID-19 patients.","claims":[{"public_id":"cl_9eec8b308cb6044e91bf4231b254811a","status":"active","text":"Following aaPRP administration, C-reactive protein (CRP) values decreased significantly while the lymphocyte-to-CRP ratio (LCR) and neutrophil-lymphocyte ratio (NLR) slightly increased.","confidence":0.85,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_9eec8b308cb6044e91bf4231b254811a"},{"public_id":"cl_1093e947dd59b05524b2d59e3f901e75","status":"active","text":"Nine of ten severe COVID-19 patients treated with aaPRP recovered and were transferred from the ICU to the ward, while one patient died in the ICU due to heart failure.","confidence":0.9,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_1093e947dd59b05524b2d59e3f901e75"},{"public_id":"cl_b63a7cedbc46be3c1639bf1f663b44af","status":"active","text":"Ten severe COVID-19 patients admitted to the ICU received autologous activated platelet-rich plasma (aaPRP) administered three times in a phase I/II trial.","confidence":0.9,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_b63a7cedbc46be3c1639bf1f663b44af"},{"public_id":"cl_bc61d98ac00effa2d9bf27d2a17808b6","status":"active","text":"aaPRP administration in severe COVID-19 patients was safe and not associated with serious adverse events, supporting its potential as an adjunctive therapy.","confidence":0.8,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_bc61d98ac00effa2d9bf27d2a17808b6"}],"concepts":[{"public_id":"co_2ec40f50380d06c91364993c7c9e3bc6","status":"active","name":"C-reactive protein (CRP)","description":"A blood inflammatory marker measured as a secondary outcome in this trial.","types":["biomarker"],"aliases":["CRP"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_2ec40f50380d06c91364993c7c9e3bc6"},{"public_id":"co_34cd65d57444688df84ddc213e80661e","status":"active","name":"mortality","description":"The primary outcome tracking patient death during ICU treatment in this trial.","types":["outcome"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_34cd65d57444688df84ddc213e80661e"},{"public_id":"co_49f489ced3248a8c24026ff877064fc4","status":"active","name":"severe COVID-19 patients","description":"The cohort of ten hospitalized patients with severe Coronavirus Disease 2019 who were enrolled and treated in this trial.","types":["population"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_49f489ced3248a8c24026ff877064fc4"},{"public_id":"co_5e9247defc55505e91a539658e2d0cae","status":"active","name":"proinflammatory cytokine production","description":"The increased generation of inflammatory cytokines in COVID-19 that drives the cytokine storm described in this paper.","types":["phenomenon"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_5e9247defc55505e91a539658e2d0cae"},{"public_id":"co_65a7f9b6b5507edc45394e2a48cca093","status":"active","name":"Phase I/II clinical trial","description":"The early-stage clinical trial design used in this study to assess the safety and efficacy of aaPRP.","types":["study design"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_65a7f9b6b5507edc45394e2a48cca093"},{"public_id":"co_6b764b343073c5812630f967a3bd74ab","status":"active","name":"neutrophil-lymphocyte ratio (NLR)","description":"A ratio of neutrophil to lymphocyte counts used as a secondary outcome marker of inflammation in this trial.","types":["biomarker"],"aliases":["NLR"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_6b764b343073c5812630f967a3bd74ab"},{"public_id":"co_af493fac30d35b95f67b8510340a372e","status":"active","name":"lymphocyte-to-CRP ratio (LCR)","description":"A ratio of lymphocyte count to CRP level used as a secondary outcome marker in this trial.","types":["biomarker"],"aliases":["LCR"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_af493fac30d35b95f67b8510340a372e"},{"public_id":"co_f19c7ac4ef37d2927147d0e23303ee2e","status":"active","name":"cytokine storm","description":"An excessive, dysregulated release of proinflammatory cytokines associated with severe COVID-19 that aaPRP was intended to suppress.","types":["phenomenon"],"aliases":["cytokine release syndrome","CRS"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_f19c7ac4ef37d2927147d0e23303ee2e"},{"public_id":"co_f46569febe89f219b96337464592cece","status":"active","name":"intensive care unit (ICU)","description":"The hospital unit where the severe COVID-19 patients in this trial were admitted and treated.","types":["clinical setting"],"aliases":["ICU"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_f46569febe89f219b96337464592cece"},{"public_id":"co_f8aa12458bea8cdd91e2deb304b7a6fb","status":"active","name":"autologous activated platelet-rich plasma (aaPRP)","description":"A blood-derived autologous product enriched with activated platelets, growth factors, and anti-inflammatory cytokines, administered as the treatment intervention in this trial.","types":["therapeutic intervention"],"aliases":["aaPRP"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_f8aa12458bea8cdd91e2deb304b7a6fb"}],"external_ids":{"DOI":"10.1155/2021/5531873","ArXiv":null,"PubMed":34306612,"PubMedCentral":"8285191","MAG":null,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://downloads.hindawi.com/journals/iji/2021/5531873.pdf","landing_url":"https://www.semanticscholar.org/paper/28b48203ead5503ad15f5cc4e8488d47b25a7398","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632292,"paper_uid":"ae75c5d2-e339-4e0e-b752-b2f01cd01ab8","canonical_identity":{"paper_id":632292,"paper_uid":"ae75c5d2-e339-4e0e-b752-b2f01cd01ab8","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/235887814"}